Significance of Bcl-2 and Bcl-6 Immunostaining in B-Non Hodgkin's lymphoma

Abstract

The determination of prognosis for B-Non-Hodgkin's lymphoma (NHL) is known to be related to the multiple differences in tumor cell biology. Bcl-2 and Bcl-6 are two markers linked to germinal center B cells. Both markers are thought to have an effect on prognosis of mature B-cell neoplasms. Forty-four patients with chronic B-cell neoplasm were included; Bcl-2 and Bcl-6 expression by immunohistochemistry was examined. Bcl-2 protein was positive in 36.4% (16 of 44) of cases (62.5% of follicular lymphoma, 16.7% of mantle cell lymphoma and 30% of diffuse large B-cell lymphoma); the positive group implying a bad prognostic effect of the marker in NHL. Bcl-6 was positive in 13.6% (6 of 44) of cases (11.1% of mantle cell lymphoma and 40% of diffuse large B-cell lymphoma) and its positivity implies a better disease course. Bcl-2 and Bcl-6 can be used as prognostic marker in NHL.

Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study

“…These two proteins are frequently found in B‐cell NHL, and both should be considered as reliable prognostic markers. Although some reports failed to show any impact of BCL2 protein expression on survival , subsequent studies have reported that BCL2‐positive cases have a worse prognosis , which is in line with the data presented herein for patients who underwent R‐B immunochemotherapy. Until now, published data regarding expression of BCL6 were conflicting because some authors observed a negative impact on the outcome of B‐cell lymphoma , whereas others did not .…”

An Autopsy Case of Epstein-Barr Virus–Associated Diffuse Large B-Cell Lymphoma of the Central Nervous System in an Immunocompromised Host

“…The tumor cells were robustly positive for CD20 and Bcl-2; however, they were negative for CD3, Bcl-6, CD10, MUM-1, and CMV. Bcl-6 and CD10 are usually positive in germinal center type DLBCL and Bcl-6 can be considered as a good prognostic marker, but our case was negative for these two markers [ 13 ]. MUM-1 is usually positive in activated B-cell type of DLBCL [ 14 ], but it was also negative in our case.…”

COVID19-induced immunosuppression and aggressive progression of primary cranial vault lymphoma presenting as a management challenge, a case report, and a literature review

“…Faster progression of the tumor was reflected by high KI-67 proliferation index, but one good prognostic feature was the absence of BCL-2 staining, which helps in good chemotherapy and radiotherapy response as reported in different studies [ 9 ]. In the previous, reported cases mimicking meningioma BCL-2 staining in FISH were presented, suggesting a poor response to treatment [ 3 , 8 ].…”